Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck
Pembrolizumab plus docetaxel and cisplatin reveals encouraging survival benefit with a manageable safety profile in patients with HNSCC.
Authors
- Zhendong Li (ORCID: https://orcid.org/0000-0002-3930-2888)
- WenQian Zhang (ORCID: https://orcid.org/0000-0003-4009-303X)
- Jing Wang (ORCID: https://orcid.org/0000-0002-0790-100X)
- Zhu Liu (ORCID: https://orcid.org/0000-0002-0074-1453)
- Wei Zhang (ORCID: https://orcid.org/0000-0003-0548-6348)
- Dongning Huang (ORCID: https://orcid.org/0000-0001-8075-4264)
Institutions
- Shanghai Public Health Clinical Center (CN)
- Liaoning Cancer Hospital & Institute (CN)
- China Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1664892
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00